XTX Topco’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

XTX Topco’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,574	Closed	-$41K	–	1044
2021 Q4	$41K	Buy	15,574 +4,359	+39%	+$13.2K	0.02%	584
2021 Q3	$35K	Buy	+11,215	New	+$37.4K	0.01%	623

Other funds holding PHAS

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Towercrest Capital Management Newtown, Pennsylvania $642M AUM 11.71% 1-Year Est. Return

Vericrest Private Wealth Newtown, Pennsylvania $111M AUM

XTX Topco's PHAS Position: Q1 2022 in Review

XTX Topco sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 15,574 shares — an estimated $41K sold.

XTX Topco first reported a position in PHAS in Q3 2021 and held it in 2 quarters. The position peaked at $41K in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

XTX Topco reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
XTX Topco sold 15,574 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $41K.
XTX Topco first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
XTX Topco's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $41K in Q4 2021.
56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on XTX Topco's 13F filing for Q1 2022, filed 13 May 2022.